ARCHIVES

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

This article is from The Cancer Letter archive.

Vol. 31 No. 21 | May 27, 2005

Download PDF Visit The Full Archive

Related Articles

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

December 27, 2013

NIH Returns to Play Catch Up “After 16 Costly, Wasteful Days”

October 18, 2013

Plan To Reprogram $10 Million On Construction Funds Draws Criticism

November 19, 1976

NEJM Says Henschke Conflicts Irrelevant; Propriety Of Granting CME Questioned.

March 14, 2008

Blincyto Demonstrates Response In Minimal Residual Disease ALL

December 26, 2014

AACR Academy Names 2014 Class of Fellows

April 4, 2014